Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_assertion type Assertion NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_head.
- NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_assertion description "[Therefore, inhibitors of transglutaminase 2 should be considered as possible therapeutics for OPMD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_provenance.
- NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_assertion evidence source_evidence_literature NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_provenance.
- NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_assertion SIO_000772 20519718 NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_provenance.
- NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_assertion wasDerivedFrom befree-2016 NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_provenance.
- NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_assertion wasGeneratedBy ECO_0000203 NP816282.RArIeXwyVhSqs6KiaEKOk5E045jgSxjlShb6ujz65mZD4130_provenance.